メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

  • Emmanuel S. Antonarakis
  • , Se Hoon Park
  • , Jeffrey C. Goh
  • , Sang Joon Shin
  • , Jae Lyun Lee
  • , Niven Mehra
  • , Ray Mcdermott
  • , Núria Sala-Gonzalez
  • , Peter C. Fong
  • , Richard Greil
  • , Margitta Retz
  • , Juan Pablo Sade
  • , Patricio Yanez
  • , Yi Hsiu Huang
  • , Stephen D. Begbie
  • , Rustem Airatovich Gafanov
  • , Maria De Santis
  • , Eli Rosenbaum
  • , Michael P. Kolinsky
  • , Felipe Rey
  • Kun Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian H. Poehlein, Evan Y. Yu

研究成果: ジャーナルへの寄稿学術論文査読

フィンガープリント

「Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases